Clinical Trial: MD1003-AMN MD1003 in Adrenomyeloneuropathy

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional




Official Title: MD1003 in Adrenomyeloneuropathy : a Randomized Double Blind Placebo Controlled Study

Brief Summary: The primary objective of the trial is to demonstrate the superiority of biotin at 300 mg/day over placebo in the clinical improvement (walking tests) of patients with adrenomyeloneuropathy